For the second time in a year, the US Food and Drug Administration has reprimanded CytoDyn, Inc. for making claims about the efficacy of its investigational drug leronlimab for treatment of COVID-19. The agency went further this time, with the Office of Prescription Drug Promotion issuing a warning letter to the company demanding that it submit a plan to disseminate a corrective communication.
In a 11 February letter, OPDP objected to a video interview in which then CytoDyn president and CEO Nader...